Betalin Therapeutics
Tissue Engineering for Insulin Therapy Alternative
Company Overview
Snapshot
Founded in July 2015 by Shuki Joshua Hershcovich and Shay Hershcovich, Betalin Therapeutics operates with 1–10 employees. The company has raised a total of $11.06 million across six funding rounds from three investors.
Business overview
Betalin Therapeutics is a Health Tech & Life Sciences company focused on developing an alternative to insulin injections and glucose testing for diabetes patients. The company's core product is the proprietary Engineered Micro Pancreas (EMP), which creates connective tissue to enable the body's beta cells to function correctly and produce adequate insulin. Betalin Therapeutics serves the global healthcare market, targeting patients with chronic conditions, particularly diabetes, through its biopharmaceutical and biotechnology solutions.
Strategic signal
In July 2023, Betalin Therapeutics made progress on its micro pancreas technology for Type 1 diabetes treatment, as reported by Ynetnews. This development signals continued advancement in the company's core therapeutic area, potentially validating its tissue engineering approach and indicating a positive trajectory towards clinical viability and market impact for diabetes care.
Log in to access full profile ›Company Intelligence Q&A
- What is Betalin Therapeutics' primary focus?
- Betalin Therapeutics focuses on developing an alternative to insulin injections and glucose testing for diabetes patients through its proprietary Engineered Micro Pancreas (EMP) technology.
- When was Betalin Therapeutics founded and by whom?
- Betalin Therapeutics was founded in July 2015 by Shuki Joshua Hershcovich and Shay Hershcovich.
- What was a significant recent funding event for Betalin Therapeutics?
- In February 2024, Betalin Therapeutics secured an equity crowdfunding round led by.
- Has Betalin Therapeutics received any grants?
- Yes, in January 2021, Betalin Therapeutics received a grant from EU Horizon 2020. Another grant was received from EU Horizon 2020 in September 2020.
- What is the status of Betalin Therapeutics' product development?
- Betalin Therapeutics' Engineered Micro Pancreas (EMP) is currently in the clinical trial stage, with progress reported in July 2023 regarding its potential to revolutionize Type 1 diabetes treatment.